Results 71 to 80 of about 178,517 (322)

Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation

eJHaem, 2022
Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor‐treatment naïve patients.
Lone Schejbel, Marie Fredslund Breinholt, Anne Ortved Gang, Torsten Holm Nielsen, Lars Møller Pedersen, Estrid Høgdall, Peter Nørgaard   +6 more
doaj   +1 more source

Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease

Drugs, 2021
Systemic autoimmune disorders are complex heterogeneous chronic diseases involving many different immune cells. A significant proportion of patients respond poorly to therapy.
S. F. Neys, J. Rip, R. Hendriks, O. Corneth   +3 more
semanticscholar   +1 more source

Lymphocyte Development: Intrinsic checkpoints for lineage progression [PDF]

, 1995
A new T-cell receptor α-chain-like molecule has been identified in precursor T cells.
Alt, Anderson, Aoki, Ashwell, Bossy, Brouns, Chan, Desiderio, deWeers, Gold, Groettrup, Groettrup, Hivroz, Karasuyama, Kinnon, Kitamura, Koch, Kruisbeek, Kudo, Levin, Loffert, Melchers, Melchers, Molina, Mombaerts, Mombaerts, Nossal, Pfeffer, Philcott, Saint-Ruf, Saouaf, Shinkai, Swan, Tsubata, von Boehmer, Weiss   +35 more
core   +1 more source

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Biomarker Insights, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Nadine Kutsch, Reinhard Marks, Richard Ratei, Thomas K. Held, Martin Schmidt-Hieber   +4 more
doaj   +1 more source

Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

Journal of Medicinal Chemistry, 2019
Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by ...
R. Caldwell, Hui Qiu, B. Askew, Andrew T. Bender, N. Brugger, M. Camps, M. Dhanabal, Vikram Dutt, T. Eichhorn, A. Gardberg, A. Goutopoulos, R. Grenningloh, J. Head, B. Healey, Brian L. Hodous, B. Huck, Theresa L. Johnson, Christopher Jones, Reinaldo C Jones, I. Mochalkin, F. Morandi, Ngan Nguyen, M. Meyring, Justin R. Potnick, Dusica Santos, R. Schmidt, B. Sherer, A. Shutes, K. Urbahns, A. Follis, A. Wegener, S. Zimmerli, L. Liu-Bujalski   +32 more
semanticscholar   +1 more source

Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease

Acta Neuropathologica, 2020
Anti-CD20-mediated B-cell depletion effectively reduces acute multiple sclerosis (MS) flares. Recent data shows that antibody-mediated extinction of B cells as a lasting immune suppression, harbors the risk of developing humoral deficiencies over time ...
Sebastian Torke, Roxanne Pretzsch, Darius Häusler, P. Haselmayer, R. Grenningloh, U. Boschert, W. Brück, Martin S. Weber   +7 more
semanticscholar   +1 more source

A distinct role for B1b lymphocytes in T cell-independent immunity [PDF]

, 2008
Pathogenesis of infectious disease is not only determined by the virulence of the microbe but also by the immune status of the host. Vaccination is the most effective means to control infectious diseases.
A Faili, A Scorpio, A Vink, A Zandvoort, A Zandvoort, AA Belperron, AB Kantor, AB Kantor, AB Satterthwaite, AF Ochsenbein, AG Barbour, AG Barbour, AM Stall, C Janeway, CA Jefferies, CA Jefferies, CD Landers, CG Vinuesa, CG Vinuesa de, CM Snapper, D Cadavid, D Tarlinton, DD Pinschewer, DE Briles, DE Mosier, DE Mosier, DF Amsbaugh, DF Kelly, DF Kelly, E Fikrig, E Montecino-Rodriguez, E Montecino-Rodriguez, E Szomolanyi-Tsuda, E Szomolanyi-Tsuda, E Szomolanyi-Tsuda, EA Kurt-Jones, EA Leadbetter, ES Shang, F Martin, F Martin, F Martin, G Muller, GB Lesinski, H Toyama, HC Selinka, I Scher, IC MacLennan, J Andersson, J Chinen, J Couderc, JA Gebbia, JC Garcia-Monco, JD Thomas, JR Hiernaux, JW Tung, K Takeda, KM Ansel, KM Haas, KM Toellner, KR Alugupalli, KR Alugupalli, KR Alugupalli, KR Alugupalli, KR Alugupalli, KR Alugupalli, L Knoops, LJ McHeyzer-Williams, M Balasz, M Boes, M Muramatsu, M Schnare, M Yokota, MA Breukels, MC Hsu, MG McHeyzer-Williams, MS Cabatingan, N Maizels, N Maizels, N Watanabe, NL Bernasconi, NW Schroder, P Dullforce, PM Southern Jr, PW Yu, Q Vos, R Berland, R Guinamard, R Malley, RB Corley, RH Carter, RH Carter, RL Chelvarajan, RL Chelvarajan, RL Chelvarajan, RL Chelvarajan, RL Chelvarajan, RM Zinkernagel, RT Woodland, RT Woodland, S Bondada, S Fagarasan, S Kruetzmann, S Weller, SA Ha, SE Connolly, SE Connolly, SH Feng, SR Yan, SR Yan, T Fehr, T Kawai, T Mizuno, T Mizuno, TL Carvalho, TT Wang, TV Obukhanych, UC Tornberg, UE Hopken, W Ellmeier, WN Khan, WN Khan, Y Arimitsu, Y Chong, Y Nagai   +123 more
core   +2 more sources

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny

British Journal of Pharmacology
AbstractBruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B‐cell proliferative disorders. An impressive programme of drug discovery and clinical development led to the approval of covalent and non‐covalent Btk inhibitors that became pillars of treatment of such ...
Giorgio, Minotti, Massimiliano, Camilli, Emanuela, Salvatorelli, Pierantonio, Menna   +3 more
openaire   +2 more sources

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Refractory immune thrombocytopenic purpura associated with IgM monoclonal gammopathy of undetermined significance: Successful treatment with tirabrutinib plus conventional therapies

eJHaem, 2022
When immune thrombocytopenia (ITP) is secondary to malignant diseases, chemotherapy is expected to improve the platelet count (PC) as well. Herein, we report a case of a 72‐year‐old man with ITP refractory to standard therapies. IgM monoclonal gammopathy
Ryosuke Naka, Hitomi Kaneko, Osamu Nagata, Kohei Tada, Masaharu Tashima, Chisato Mizutani, Kazunori Imada   +6 more
doaj   +1 more source